Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.61 |
| ▸ | JAK3 | P52333 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 16/20 | 0.60 |
| ▸ | ITK | Q08881 | 5/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16370927 | 0.93 | BTK (0.60) | BTKJAK3EGFRITK | |
| SCHEMBL16706331 | 0.93 | BTK (0.62) | BTKJAK3EGFRITK | |
| SCHEMBL16706323 | 0.91 | BTK (0.60) | BTKJAK3EGFRITK | |
| SCHEMBL16706333 | 0.90 | BTK (0.61) | BTKJAK3EGFRITK | |
| SCHEMBL16371003 | 0.89 | BTK (0.64) | BTKJAK3EGFRITK | |
| SCHEMBL19976710 | 0.86 | BTK (0.69) | BTKJAK3EGFRITK | |
| SCHEMBL21338050 | 0.85 | BTK (0.68) | BTKJAK3EGFRITK | |
| SCHEMBL12519542 | 0.85 | EGFR (0.79) | BTKJAK3EGFRITK | |
| SCHEMBL16391125 | 0.85 | BTK (0.61) | BTKJAK3EGFRITK | |
| SCHEMBL16370813 | 0.84 | EGFR (0.69) | BTKJAK3EGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920074-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170029442-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
| US-9464089-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029442-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BMX, BLK, BTK | BTK 3/4885JAK3 30/4885EGFR 16/4885 |
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BMX, BLK, BTK | BTK 3/4885JAK3 30/4885EGFR 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.